Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 18, 2024

Efficacy of Olaparib ± Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Patients With Advanced TNBC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Clin. Cancer Res 2024 Jan 18;[EPub Ahead of Print], TJ Tan, S Sammons, YH Im, L She, K Mundy, R Bigelow, TA Traina, C Anders, J Yeong, E Renzulli, SB Kim, R Dent

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading